Dr. Sagar Lonial, a myeloma specialist at Emory's Winship Cancer Institute, is excited about new drugs in trials and research making news at ASH in 2011. He covers the promising medication carfilzomib, slated for FDA review by July 2012; third-generation IMiD, pomalidomide; and combination therapy with the monoclonal antibody, elotuzumab. He also touches on research into the use of HDAC inhibitors to help overcome bortezomib resistance and a possible oral proteasome inhibitor.
Link to this comment:
All Comments (0)